Preferred Label : Idecabtagene Vicleucel;
NCIt synonyms : Anti-BCMA CAR T Cells BB2121; BCMA-specific CAR-expressing T Lymphocytes BB2121; Ide-cel; Anti-BCMA-CAR-transduced T Cells BB2121;
NCIt definition : A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been
genetically modified to express a chimeric antigen receptor (CAR) specific for the
B-cell maturation antigen (BCMA), with potential immunostimulating and antineoplastic
activities. Upon administration, idecabtagene vicleucel specifically recognizes and
kills BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for
both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF),
is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a
key role in plasma survival; it is found on the surfaces of plasma cells and overexpressed
on malignant plasma cells.;
UNII : 8PX1X7UG4D;
Drug name : Abecma;
Molecule name : BB2121;
NCI Metathesaurus CUI : CL474124;
Codes from synonyms : 23426;
Origin ID : C117729;
UMLS CUI : C3899973;
Currated CISMeF NLP mapping
Semantic type(s)
- Cell [UMLS semantic type]
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
chemical_or_drug_affects_cell_type_or_tissue
chemical_or_drug_has_mechanism_of_action
chemical_or_drug_has_physiologic_effect
concept_is_in_subset
has_target
is_component_of_chemotherapy_regimen
https://ansm.sante.fr/tableau-atu-rtu/abecma-260-500-x-106-cellules-dispersion-pour-perfusion
2025
false
false
false
France
French
guidelines for drug use
Idecabtagene Vicleucel
Idecabtagene Vicleucel
gene therapy
immunotherapy, adoptive
adult
multiple myeloma
recurrence
Refractory Multiple Myeloma
idecabtagene vicleucel
idecabtagene vicleucel
Recurrent Multiple Myeloma
genetic therapy
---
https://www.cadth.ca/fr/idecabtagene-vicleucel
2021
false
false
false
Canada
French
English
gene therapy
Idecabtagene Vicleucel
multiple myeloma
drug information
idecabtagene vicleucel
idecabtagene vicleucel
genetic therapy
---
https://www.has-sante.fr/jcms/p_3303102/fr/abecma-idecabtagene-vicleucel-myelome-multiple
https://has-sante.fr/jcms/p_3303143/fr/decision-n-2021-0311/dc/sem-du-2-decembre-2021-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-abecma-idecabtagene-vicleucel
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
Antineoplastic Agents, Immunological
Idecabtagene Vicleucel
Idecabtagene Vicleucel
Receptors, Chimeric Antigen
immunotherapy, adoptive
adult
recurrence
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
infusions, intravenous
Triple-Class Refractory Multiple Myeloma
idecabtagene vicleucel
idecabtagene vicleucel
evaluation of the transparency committee
multiple myeloma
---
https://www.ema.europa.eu/en/medicines/human/EPAR/abecma
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Idecabtagene Vicleucel
Idecabtagene Vicleucel
Receptors, Chimeric Antigen
Receptors, Chimeric Antigen
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
gene therapy
orphan drug production
multiple myeloma
adult
Refractory Multiple Myeloma
recurrence
infusions, intravenous
continuity of patient care
Cytokine Release Syndrome
Drug-Related side effects and adverse reactions
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Triple-Class Refractory Multiple Myeloma
idecabtagene vicleucel
idecabtagene vicleucel
---
Abecma (idecabtagene vicleucel): Authorization with conditions
https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medeffet-canada/infovigilance-produits-sante/juin-2021.html#a5.3
2021
false
false
false
Canada
French
English
drug approval
canada
Idecabtagene Vicleucel
gene therapy
infusions, intravenous
multiple myeloma
adult
drug information
idecabtagene vicleucel
idecabtagene vicleucel
genetic therapy
---